FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385877503> ?p ?o ?g. }

• W4385877503 abstract "<p>ICOS agonist mAbs demonstrate improved antitumor activity in combination with PD-1 blockade. EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)], anti-PD-1 mAb (RMP1-14), or isotype controls (mIgG1 and rat IgG2a, respectively) alone and in combination for a total of six doses. Mice were evaluated for pharmacodynamic changes (<b>B</b> and <b>C</b>) within tumors, tumor growth (<b>D</b>), and survival (<b>E</b>). As illustrated in <b>A</b>, transcriptional analysis was performed (<i>n</i> = 5–7) on tumor tissue harvested from mice 48 hours after second (<b>B</b>) and third doses (<b>C</b>) of indicated mAbs; raw data in <a href=#SMT4 target=_blank>Supplementary Table S4</a>. Each line in <b>D</b> represents an individual mouse (<i>n</i> = 10/group). Tumor-free mice at study termination are indicated within each subpanel. <b>E,</b> Kaplan–Meier plot illustrating OS in D. <b>F,</b><i>ICOS</i> expression following <i>ex vivo</i> anti–PD-1 (pembrolizumab) or vehicle control treatment of tumor slices from patients with HNSCC for 48 hours. Each symbol represents an individual human tumor sample (<i>n</i> = 50/group). <b>G,</b> Fold change in IFNγ production by TILs from dissociated NSCLC tumor samples (<i>n</i> = 5–6 samples/group) following exposure to anti-CD3 (plate-bound, 0.6 μg/mL) in concert with anti-PD-1 (pembrolizumab, soluble) or feladilimab (plate-bound) alone or in combination for 24 hours. <b>H,</b> A2058 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab and anti-PD-1 (pembrolizumab) alone or in combination for a total of six doses and assessed for tumor growth inhibition (<i>n</i> = 10/group). Data in F–H are represented as mean ± s.e.m. Significance in G determined by unpaired Student <i>t</i> test. Despite trends in tumor growth kinetics following combination treatment, the curves in H were not significantly different as determined by one-way ANOVA. ANOVA, analysis of variance; HNSCC, head and neck squamous cell carcinoma; ICOS, inducible T cell costimulator; IFN, interferon; i.p., intraperitoneal injection; mAb, monoclonal antibody; NSCLC, non–small cell lung carcinoma; OS, overall survival; PD-1, programmed cell death protein 1; s.e.m., standard error of the mean; TIL, tumor-infiltrating lymphocyte.</p>" @default.
• W4385877503 created "2023-08-17" @default.
• W4385877503 creator A5000219610 @default.
• W4385877503 creator A5001962000 @default.
• W4385877503 creator A5004021303 @default.
• W4385877503 creator A5004072228 @default.
• W4385877503 creator A5015114773 @default.
• W4385877503 creator A5015668076 @default.
• W4385877503 creator A5018536695 @default.
• W4385877503 creator A5022516918 @default.
• W4385877503 creator A5026700573 @default.
• W4385877503 creator A5027408575 @default.
• W4385877503 creator A5027768129 @default.
• W4385877503 creator A5029679351 @default.
• W4385877503 creator A5038356599 @default.
• W4385877503 creator A5038887077 @default.
• W4385877503 creator A5039345673 @default.
• W4385877503 creator A5045119909 @default.
• W4385877503 creator A5046901107 @default.
• W4385877503 creator A5049176429 @default.
• W4385877503 creator A5053416448 @default.
• W4385877503 creator A5059006181 @default.
• W4385877503 creator A5059747154 @default.
• W4385877503 creator A5060469120 @default.
• W4385877503 creator A5060590115 @default.
• W4385877503 creator A5062799755 @default.
• W4385877503 creator A5062921585 @default.
• W4385877503 creator A5063142060 @default.
• W4385877503 creator A5069580658 @default.
• W4385877503 creator A5073127295 @default.
• W4385877503 creator A5076409863 @default.
• W4385877503 creator A5085886223 @default.
• W4385877503 creator A5086481435 @default.
• W4385877503 creator A5088225387 @default.
• W4385877503 creator A5092500577 @default.
• W4385877503 creator A5092501031 @default.
• W4385877503 creator A5092502045 @default.
• W4385877503 date "2023-08-16" @default.
• W4385877503 modified "2023-09-27" @default.
• W4385877503 title "FIGURE 4 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade" @default.
• W4385877503 doi "https://doi.org/10.1158/2767-9764.23968502" @default.
• W4385877503 hasPublicationYear "2023" @default.
• W4385877503 type Work @default.
• W4385877503 citedByCount "0" @default.
• W4385877503 crossrefType "posted-content" @default.
• W4385877503 hasAuthorship W4385877503A5000219610 @default.
• W4385877503 hasAuthorship W4385877503A5001962000 @default.
• W4385877503 hasAuthorship W4385877503A5004021303 @default.
• W4385877503 hasAuthorship W4385877503A5004072228 @default.
• W4385877503 hasAuthorship W4385877503A5015114773 @default.
• W4385877503 hasAuthorship W4385877503A5015668076 @default.
• W4385877503 hasAuthorship W4385877503A5018536695 @default.
• W4385877503 hasAuthorship W4385877503A5022516918 @default.
• W4385877503 hasAuthorship W4385877503A5026700573 @default.
• W4385877503 hasAuthorship W4385877503A5027408575 @default.
• W4385877503 hasAuthorship W4385877503A5027768129 @default.
• W4385877503 hasAuthorship W4385877503A5029679351 @default.
• W4385877503 hasAuthorship W4385877503A5038356599 @default.
• W4385877503 hasAuthorship W4385877503A5038887077 @default.
• W4385877503 hasAuthorship W4385877503A5039345673 @default.
• W4385877503 hasAuthorship W4385877503A5045119909 @default.
• W4385877503 hasAuthorship W4385877503A5046901107 @default.
• W4385877503 hasAuthorship W4385877503A5049176429 @default.
• W4385877503 hasAuthorship W4385877503A5053416448 @default.
• W4385877503 hasAuthorship W4385877503A5059006181 @default.
• W4385877503 hasAuthorship W4385877503A5059747154 @default.
• W4385877503 hasAuthorship W4385877503A5060469120 @default.
• W4385877503 hasAuthorship W4385877503A5060590115 @default.
• W4385877503 hasAuthorship W4385877503A5062799755 @default.
• W4385877503 hasAuthorship W4385877503A5062921585 @default.
• W4385877503 hasAuthorship W4385877503A5063142060 @default.
• W4385877503 hasAuthorship W4385877503A5069580658 @default.
• W4385877503 hasAuthorship W4385877503A5073127295 @default.
• W4385877503 hasAuthorship W4385877503A5076409863 @default.
• W4385877503 hasAuthorship W4385877503A5085886223 @default.
• W4385877503 hasAuthorship W4385877503A5086481435 @default.
• W4385877503 hasAuthorship W4385877503A5088225387 @default.
• W4385877503 hasAuthorship W4385877503A5092500577 @default.
• W4385877503 hasAuthorship W4385877503A5092501031 @default.
• W4385877503 hasAuthorship W4385877503A5092502045 @default.
• W4385877503 hasBestOaLocation W43858775031 @default.
• W4385877503 hasConcept C153911025 @default.
• W4385877503 hasConcept C159654299 @default.
• W4385877503 hasConcept C170493617 @default.
• W4385877503 hasConcept C185592680 @default.
• W4385877503 hasConcept C203014093 @default.
• W4385877503 hasConcept C2778453870 @default.
• W4385877503 hasConcept C2778468042 @default.
• W4385877503 hasConcept C55493867 @default.
• W4385877503 hasConcept C71924100 @default.
• W4385877503 hasConcept C86803240 @default.
• W4385877503 hasConceptScore W4385877503C153911025 @default.
• W4385877503 hasConceptScore W4385877503C159654299 @default.
• W4385877503 hasConceptScore W4385877503C170493617 @default.
• W4385877503 hasConceptScore W4385877503C185592680 @default.
• W4385877503 hasConceptScore W4385877503C203014093 @default.
• W4385877503 hasConceptScore W4385877503C2778453870 @default.
• W4385877503 hasConceptScore W4385877503C2778468042 @default.
• W4385877503 hasConceptScore W4385877503C55493867 @default.
• W4385877503 hasConceptScore W4385877503C71924100 @default.

• next